TG Therapeutics Inc (TGTX)
19.01
+0.22
(+1.17%)
USD |
NASDAQ |
Jul 05, 16:00
19.28
+0.27
(+1.42%)
Pre-Market: 09:12
TG Therapeutics Research and Development Expense (TTM): 93.05M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 93.05M |
| December 31, 2023 | 76.19M |
| September 30, 2023 | 88.38M |
| June 30, 2023 | 94.43M |
| March 31, 2023 | 93.18M |
| December 31, 2022 | 125.35M |
| September 30, 2022 | 158.36M |
| June 30, 2022 | 189.53M |
| March 31, 2022 | 207.53M |
| December 31, 2021 | 222.58M |
| September 30, 2021 | 202.89M |
| June 30, 2021 | 201.39M |
| March 31, 2021 | 192.97M |
| December 31, 2020 | 165.90M |
| September 30, 2020 | 153.88M |
| June 30, 2020 | 161.40M |
| March 31, 2020 | 157.82M |
| December 31, 2019 | 154.18M |
| September 30, 2019 | 175.51M |
| June 30, 2019 | 150.92M |
| March 31, 2019 | 156.76M |
| December 31, 2018 | 159.39M |
| September 30, 2018 | 133.11M |
| June 30, 2018 | 126.86M |
| March 31, 2018 | 114.87M |
| Date | Value |
|---|---|
| December 31, 2017 | 102.53M |
| September 30, 2017 | 98.82M |
| June 30, 2017 | 93.47M |
| March 31, 2017 | 80.30M |
| December 31, 2016 | 69.23M |
| September 30, 2016 | 62.20M |
| June 30, 2016 | 51.98M |
| March 31, 2016 | 49.71M |
| December 31, 2015 | 47.71M |
| September 30, 2015 | 47.59M |
| June 30, 2015 | 49.71M |
| March 31, 2015 | 45.29M |
| December 31, 2014 | 40.09M |
| September 30, 2014 | 28.71M |
| June 30, 2014 | 18.32M |
| March 31, 2014 | 16.50M |
| December 31, 2013 | 13.66M |
| September 30, 2013 | 10.99M |
| June 30, 2013 | 9.238M |
| March 31, 2013 | 5.856M |
| December 31, 2012 | 21.03M |
| September 30, 2012 | 19.96M |
| June 30, 2012 | 18.42M |
| March 31, 2012 | 17.07M |
| December 31, 2011 | 17.40M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
76.19M
Minimum
Dec 2023
222.58M
Maximum
Dec 2021
153.40M
Average
158.36M
Median
Sep 2022
Research and Development Expense (TTM) Benchmarks
| Eli Lilly and Co | 9.851B |
| Alnylam Pharmaceuticals Inc | 1.035B |
| Cytokinetics Inc | -- |
| Amicus Therapeutics Inc | 139.21M |
| Insmed Inc | 564.23M |